Strategies for Ovarian Cancer Prevention

Obstetrics and Gynecology Clinics of North America

Volumn 34, Issue 4, 2007, Pages 667-686

  Dann, Rebecca Byler ^a   Kelley, Joseph L ^a   Zorn, Kristin K ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; CA 72-4 ANTIGEN; COLONY STIMULATING FACTOR 1; FENRETINIDE; GESTAGEN; LYSOPHOSPHATIDIC ACID; ORAL CONTRACEPTIVE AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN SYNTHASE INHIBITOR; RETINOID; VITAMIN D;

BREAST CANCER; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOPROPHYLAXIS; DRUG EFFECT; GENE MUTATION; GYNECOLOGIC CANCER; HORMONE SUBSTITUTION; HUMAN; OVARY CANCER; PAPANICOLAOU TEST; PARITY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SALPINGOOOPHORECTOMY; TRANSVAGINAL ECHOGRAPHY; UTERINE TUBE LIGATION;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GERM-LINE MUTATION; HUMANS; MASS SCREENING; OVARIAN NEOPLASMS; OVARIECTOMY; PHYSICAL EXAMINATION; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; ULTRASONOGRAPHY;

EID: 36549090088     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ogc.2007.10.001     Document Type: Review

References (142)

1. Ries L.A.G., Hankey B.F., Miller B.A., et al. Cancer statistics review: 1973-1988 vol. 91 (1991), National Cancer Institute, NIH Publication, Bethesda (MD) p. 2789
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
3. Hogg R., and Friedlander M. Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol 22 7 (2004) 1315-1327
4. Hankinson S.E., Colditz G.A., Hunter D.J., et al. A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer 76 2 (1995) 284-290
5. Whittemore A.S., Harris R., and Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of twelve U.S case-control studies II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 136 10 (1992) 1212-1220
6. John E.M., Whittemore A.S., Harris R., et al. Characteristics relating to ovarian cancer risk: collaborative analysis of seven U.S. case-control studies. Epithelial ovarian cancer in black women. Collaborative Ovarian Cancer Group. J Natl Cancer Inst 85 2 (1993) 142-147
7. McLaughlin J.R., Risch H.A., Lubinski J., et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 8 1 (2007) 26-34
8. Brose M.S., Rebbeck T.R., Calzone K.A., et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94 18 (2002) 1365-1372
9. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91 (1999) 1310-1316
10. Antoniou A., Pharoah P.D., Narod S., et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72 5 (2003) 1117-1130
11. Easton D.F., Ford D., Bishop T., et al. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 56 1 (1995) 265-271
12. Ford D., Easton D.F., Stratton M., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62 3 (1998) 676-689
13. Ford D., Easton D.F., Bishop D.T., et al. Risks of cancer in BRCA1-mutation carriers. Lancet 343 8889 (1994) 692-695
14. Ford D., Easton D.F., and Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57 6 (1995) 1457-1462
15. Risch H.A., McLaughlin J.R., Cole D.E., et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 98 23 (2006) 1694-1706
16. Khoury-Collado F., and Bombard A.T. Hereditary breast and ovarian cancer: what the primary care physician should know. Obstet Gynecol Surv 59 7 (2004) 537-542
17. Frank T.S., Manley S.A., Olopade O.I., et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 16 7 (1998) 2417-2425
18. Greene M.H. Genetics of breast cancer. Mayo Clin Proc 72 1 (1997) 54-65
19. Shattuck-Eidens D., McClure M., Simard J., et al. A collaborative study of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene: implications for presymptomatic testing and screening. JAMA 273 7 (1995) 535-541
20. Piver M.S. Hereditary ovarian cancer: lessons learned from the first twenty years of the Gilda Radner Familial Ovarian Cancer Registry. Gynecol Oncol 85 (2002) 9-17
21. Kerlikowske K., Brown J.S., Grady D.G., et al. Should women with familial ovarian cancer undergo prophylactic oophorectomy?. Obstet Gynecol 80 4 (1992) 700-707
22. Frank T.S., Deffenbaugh A.M., Reid J.E., et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20 6 (2002) 1480-1490
23. Rubin S.C., Blackwood M.A., Bandera C., et al. BRCA1, BRCA2, and hereditary nonpolyposis colorectal gene mutations in an unselected ovarian cancer population: Relationship to family history and implications for genetic testing. Am J Obstet Gynecol 178 4 (1998) 670-677
24. Zorn K.K., Gardner G., and Birrer M.J. Epithelial ovarian cancer. In: Kelloff G.J., Hawk E.T., and Sigman C.C. (Eds). Cancer chemoprevention: strategies for cancer chemoprevention vol. 2 (2005), Humana, Totowa (NJ)
25. Bosetti C., Negri E., Trichopoulos D., et al. Long-term effects of oral contraceptives on ovarian cancer risk. Int J Cancer 102 3 (2002) 262-265
26. Tailor A., Bourne T.H., Campbell S., et al. Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study. Ultrasound Obstet Gynecol 21 4 (2003) 378-385
27. Hankinson S.E., Colditz G.A., Hunter D.J., et al. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol 80 4 (1992) 708-714
28. Modugno F., Ness R.B., and Allen G.O. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynecol 191 3 (2004) 733-734
29. Riman T., Persson I., and Nilsson S. Hormonal aspects of epithelial ovarian cancer: review of epidemiologic evidence. Clin Endocrinol 49 (1998) 695-707
30. Siskind V., Green A., Bain C., et al. Beyond ovulation: oral contraceptives and epithelial ovarian cancer. Epidemiology 11 (2000) 106-110
31. Risch H.A. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90 (1998) 1774-1786
32. Ness R.B., Grisso J.A., Klapper J., et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions. Am J Epidemiol 152 3 (2000) 233-241
33. Sanderson M., Williams M.A., Weiss N.S., et al. Oral contraceptives and epithelial ovarian cancer. Does dose matter?. J Reprod Med 45 9 (2000) 720-726
34. Lurie G., Thompson P., McDuffie K.E., et al. Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk. Obstet Gynecol 109 3 (2007) 597-607
35. Whittemore A.S., Balise R.R., Pharoah P.D., et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer 91 11 (2004) 1911-1915
36. Narod S.A., Sun P., and Risch H.A. Ovarian cancer, oral contraceptives, and BRCA mutations. N Engl J Med 345 (2001) 1706-1707
37. Walker G.R., Schlesselman J.J., and Ness R.B. Family history of cancer, oral contraceptive use, and ovarian cancer risk. Am J Obstet Gynecol 186 1 (2002) 8-14
38. Modan B., Hartge P., Hirsch-Yechezkel G., et al. Parity, oral contraceptives, and the risk of ovarian cancer among BRCA1 or BRCA2 mutation. N Engl J Med 345 4 (2001) 235-240
39. Narod S.A., Dube M.P., Klijn J., et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94 23 (2002) 1773-1779
40. Friedlander M.L. Prognostic factors in ovarian cancer. Semin Oncol 25 (1998) 305-314
41. Gordis L. Assessing the validity and reliability of diagnostic and screening tests. Epidemiology. 2nd edition (2000), W.B. Saunders, Philadelphia 63-81
42. van Nagell Jr. J.R., DePriest P.D., Puls L.E., et al. Ovarian cancer screening in asymptomatic postmenopausal women by transvaginal sonography. Cancer 68 (1991) 458-462
43. Andolf E., Jorgensen C., and Astedet B. Ultrasound examination for detection of ovarian carcinoma in risk groups. Obstet Gynecol 75 (1990) 106-109
44. Smith L.H., and Oi R.H. Detection of malignant ovarian neoplasms: a review of the literature. I. Detection of the patient at risk; clinical, radiological and cytological detection. Obstet Gynecol Surv 39 6 (1984) 313-328
45. Shapiro S.P., and Nunez C. Psammoma bodies in the cervicovaginal smear in association with a papillary tumor of the peritoneum. Obstet Gynecol 61 1 (1983) 130-134
46. Carlson K.J., Skates S.J., and Singer D.E. Screening for ovarian cancer. Ann Intern Med 121 (1994) 124-132
47. Gallup D.G., and Talledo O.E. Management of the adnexal mass in the 1990s. South Med J 90 10 (1997) 972-981
48. Mol B.W., Bayram N., Lijmer J.G., et al. The performance of CA-125 measurement in the detection of endometriosis: a meta-analysis. Fertil Steril 70 6 (1998) 1101-1108
49. Topalak O., Saygili U., Soyturk M., et al. Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study. Gynecol Oncol 85 1 (2002) 108-113
50. Zuckerman E., Lanir A., Sabo E., et al. Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis. Am J Gastroenterol 94 6 (1999) 1613-1618
51. Devarbhavi H., Kaese D., Williams A.W., et al. Cancer antigen 125 in patients with chronic liver disease. Mayo Clin Proc 77 6 (2002) 538-541
52. Bast R.C., Klug T.L., St John E., et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309 15 (1983) 883-887
53. Crump C., McIntosh M.W., Urban N., et al. Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening. Cancer Epidemiol Biomarkers Prev 9 10 (2000) 1107-1111
54. Sjovall K., Nilsson B., and Einhorn N. The significance of serum CA125 elevation in malignant and nonmalignant diseases. Gynecol Oncol 85 (2002) 175-178
55. Jacobs I.J., Skates S., Davies A.P., et al. Risk of diagnosis of ovarian cancer after raised serum CA125 concentrations: a prospective cohort study. BMJ 313 7069 (1996) 1355-1358
56. Jeyarajah A.R., Ind T.E., Skates S., et al. Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women. Cancer 85 9 (1999) 2068-2072
57. Zurawski Jr. V.R., Orjaseter H., Anderson A., et al. Elevated CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer 42 5 (1988) 677-680
58. Helzlsouer K.J., Bush T.L., Alberg A.J., et al. Prospective study of serum CA-125 levels as markers of ovarian cancer. JAMA 269 9 (1993) 1123-1126
59. Skates S.J., Menon U., MacDonald N., et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 21 Suppl 10 (2003) 206-210
60. Zurawski Jr. V.R., Sjovall K., Schoenfeld D.A., et al. Prospective evaluation of CA 125 levels in a normal population, phase I: the specificities of single and serial determinations in testing for ovarian cancer. Gynecol Oncol 36 3 (1990) 299-305
61. Einhorn N., Sjovall K., Knapp R.C., et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol 80 1 (1992) 14-18
62. Skates S.J., Horisk N., Yu Y., et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA15-3, CA72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol 22 20 (2004) 4059-4066
63. van Haaften-Day C., Shen Y., Xu F., et al. OVX1, macrophage-colony stimulating factor, and CA125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer 92 11 (2001) 2837-2844
64. Bast Jr. R.C., Knauf S., Epenetos A., et al. Coordinate elevation of serum markers in ovarian cancer but not in benign disease. Cancer 68 8 (1991) 1758-1763
65. Jacobs I.J., Oram D.H., and Bast Jr. R.C. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3. Obstet Gynecol 80 3 Pt 1 (1992) 396-399
66. Suzuki M., Ohwada M., Aida I., et al. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer. Obstet Gynecol 82 6 (1993) 946-950
67. Mor G., Visintin I., Lai Y., et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A 102 21 (2005) 7677-7682
68. Xu Y., Shen Z., Wiper D.W., et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 280 8 (1998) 719-723
69. Shen Z., Wu M., Elson P., et al. Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases. Gynecol Oncol 83 (2001) 25-30
70. Bourne T., Campbell S., Steer C., et al. Transvaginal color flow imaging: a possible new screening technique for ovarian cancer. BMJ 299 6712 (1989) 1367-1370
71. Kurjak A., Prka M., Arenas J.M., et al. Three-dimensional ultrasonography and power Doppler in ovarian cancer screening of asymptomatic peri- and postmenopausal women. Croat Med J 46 5 (2005) 757-764
72. Vuento M.H., Pirhonen J.P., Makinen J.I., et al. Evaluation of ovarian findings in asymptomatic postmenopausal women with color Doppler ultrasound. Cancer 76 7 (1995) 1214-1218
73. Weiner Z., Thaler I., Beck D., et al. Differentiating malignant from benign ovarian tumors with transvaginal color flow imaging. Obstet Gynecol 79 2 (1992) 159-162
74. Weiner Z., Beck D., Shteiner M., et al. Screening for ovarian cancer in women with breast cancer with transvaginal sonography and color flow imaging. J Ultrasound Med 12 7 (1993) 387-393
75. Van Nagell Jr. J.R., DePriest P.D., Ueland F.R., et al. Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer 109 9 (2007) 1887-1896
76. Campbell S., Royston P., Bhan V., et al. Novel screening strategies for early ovarian cancer by transabdominal ultrasonography. Br J Obstet Gynaecol 97 4 (1990) 304-311
77. Fishman D.A., Cohen L., Blank S.V., et al. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol 192 4 (2005) 1214-1221
78. Karlan B.Y., Raffel L.J., Crvenkovic G., et al. A multidisciplinary approach to the early detection of ovarian carcinoma: rationale, protocol design, and early results. Am J Obstet Gynecol 169 3 (1993) 494-501
79. Lacey Jr. J.V., Greene M.H., Buys S.S., et al. Ovarian cancer screening in women with a family history of breast or ovarian cancer. Obstet Gynecol 108 5 (2006) 1176-1184
80. Menon U., Talaat A., Rosenthal A.N., et al. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. BJOG 107 2 (2000) 165-169
81. Jacobs I.J., Skates S.J., MacDonald N., et al. Screening for ovarian cancer: a pilot randomized controlled trial. Lancet 353 9160 (1999) 1207-1210
82. Menon U., Skates S.J., Lewis S., et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 23 31 (2005) 7919-7926
83. Buys S.S., Partridge E., Greene M.H., et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 193 5 (2005) 1630-1639
84. Porok P.C., Andriole G.L., Bresalier R.S., et al. Design of the Prostate, Lung, Colorectal And Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 21 Suppl 6 (2000) 273S-309S
85. Olivier R.I., Lubsen-Brandsma M.A., Verhoef S., et al. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol 100 1 (2006) 20-26
86. Bosse K., Rhiem K., Wappenschnmidt B., et al. Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: a prospective cohort study. Gynecol Oncol 103 3 (2006) 1077-1082
87. Gaarenstroom K.N., van der Hiel B., Tollenaar R.A., et al. Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study. Int J Gynecol Cancer 16 Suppl 1 (2006) 54-59
88. Karlan B.Y., Baldwin R.L., Lopez-luevanos E., et al. Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. Am J Obstet Gynecol 180 4 (1999) 917-928
89. Meeuwissen P.A., Seynaeve C., Brekelmans C.T., et al. Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer. Gynecol Oncol 97 2 (2005) 476-482
90. Petricoin E.F., Ardekani A.M., Hitt B.A., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 9306 (2002) 572-577
91. Baggerly K.A., Morris J.S., Edmonson S.R., et al. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst 97 4 (2005) 307-309
92. Ransohoff D.F. Lessons from controversy: ovarian cancer screening and serum proteomics. J Natl Cancer Inst 97 4 (2005) 316-319
93. Rocca W.A., Grossardt B.R., de Andrade M., et al. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 7 10 (2006) 821-828
94. Domchek S.M., Friebel T.M., Neuhausen S.L., et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 7 3 (2006) 223-229
95. Levine D.A., Argenta P.A., Yee C.J., et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 21 22 (2003) 4222-4227
96. Carcangiu M.L., Peissel B., Pasini B., et al. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of literature. Am J Surg Pathol 30 10 (2006) 1222-1230
97. Finch A., Shaw P., Rosen B., et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 100 1 (2006) 58-64
98. Mcewen A.R., McConnell D.T., Kenwright D.N., et al. Occult cancer of the fallopian tube in a BRCA2 germline mutation carrier at prophylactic salpingo-oophorectomy. Gynecol Oncol 92 3 (2004) 992-994
99. Lamb J.D., Garcia R.L., Goff B.A., et al. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Am J Obstet Gynecol 194 6 (2006) 1702-1709
100. Paley P.J., Swisher E.M., Garcia R.L., et al. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol Oncol 80 2 (2001) 176-180
101. Medeiros F., Muto M.G., Lee Y., et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 30 2 (2006) 230-236
102. Olivier R.I., Lubsen-Brandsma L.A., van Boven H., et al. Additional salpingectomy after previous prophylactic oophorectomy in high-risk women: sense or nonsense?. Gynecol Oncol 96 2 (2005) 439-443
103. Powell C.B., Kenley E., Chen L.M., et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 23 1 (2005) 127-132
104. Weber A.M., Hewett W.J., Gajewski W.H., et al. Serous carcinoma of the peritoneum after oophorectomy. Obstet Gynecol 80 3 Pt 1 (1992) 558-560
105. Chen K.T., Schooley J.L., and Flam M.S. Peritoneal carcinomatosis after prophylactic oophorectomy in familial ovarian cancer syndrome. Obstet Gynecol 66 Suppl 3 (1985) 93S-94S
106. Casey M.J., and Bewtra C. Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations. Fam Cancer 3 3-4 (2004) 265-281
107. Dowdy S.C., Stefanek M., and Hartmann L.C. Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy. Am J Obstet Gynecol 191 4 (2004) 1113-1123
108. Hornreich G., Beller U., Lavie O., et al. Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature. Gynecol Oncol 75 2 (1999) 300-304
109. Lavie O., Hornreich G., Ben-Arie A., et al. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecol Oncol 92 2 (2004) 521-524
110. Goshen R., Chu W., Elit L., et al. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?. Gynecol Oncol 79 3 (2004) 477-481
111. Beiner M.E., Finch A., Rosen B., et al. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations: a prospective study. Gynecol Oncol 104 1 (2007) 7-10
112. Schmeler K., Lynch H., Chen L., et al. Prophylactic surgery to reduce the risk of gynecologic cancers in Lynch syndrome. NEJM 354 3 (2006) 261-269
113. Chen L., Yang K., Little S., et al. Gynecologic cancer prevention in Lynch dyndrome/hereditary nonpolyposis colorectal cancer families. Obstet Gynecol 110 1 (2007) 18-25
114. Olivier R.I., van Beurden M., Lubsen M.A., et al. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer 90 8 (2004) 1492-1497
115. Struewing J.P., Watson P., Easton D.F., et al. Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr 17 (1995) 33-35
116. Rutter J.L., Wacholder S., Chetrit A., et al. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: and Israeli population-based case-control study. J Natl Cancer Inst 95 14 (2003) 1072-1078
117. Olopade O.I., and Artioli G. Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations. Breast J 10 Suppl 1 (2004) S5-S9
118. Piver M.S., Jishi M.F., Tsukada Y., et al. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 71 9 (1993) 2751-2755
119. Rebbeck T.R., Lynch H.T., Neuhausen S.L., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346 21 (2002) 1616-1622
120. Kauf N.D., Satagopan J.M., Robson M.E., et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346 21 (2002) 1609-1615
121. Rosen B., Kwon J., Fung Kee Fung M., et al. Systematic review of management options for women with a hereditary predisposition to ovarian cancer. Gynecol Oncol 93 2 (2004) 280-286
122. Finch A., Beiner M., Lubinski J., et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 296 2 (2006) 185-192
123. ACOG Practice Bulletin: Prophylactic oophorectomy. Int J Gynecol Obstet 67 (1999) 193-199
124. Madalinska J.B., Hollenstein J., Bleiker E., et al. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 23 28 (2005) 6890-6898
125. Colditz G.A., Willet W.C., Stampfer M.J., et al. Menopause and the risk of coronary heart disease in women. N Engl J Med 316 18 (1987) 1105-1110
126. National Institutes of Health State-of-the-Science Conference Statement: management of menopause-related symptoms. Ann Intern Med 142 12 (2005) 1003-1013
127. Madalinska J.B., van Beurden M., Bleiker E.M., et al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol 24 22 (2006) 3576-3582
128. Rebbeck T.R., Friebel T., Wagner T., et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 23 31 (2005) 7772-7774
129. Schmeler K.M., Sun C.C., Bodurka D.C., et al. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. Obstet Gynecol 108 3 Pt 1 (2006) 515-520
130. Schwartz M.D., Kaufman E., Peshkin B.N., et al. Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. J Clin Oncol 21 21 (2003) 4034-4041
131. Ness R.B., and Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91 17 (1999) 1459-1467
132. Ness R.B., Grisso J.A., Vergona R., et al. Oral contraceptives, other methods of contraception, and risk reduction for ovarian cancer. Epidemiology 12 3 (2001) 307-312
133. Ness R.B., Grisso J.A., Cottreau C., et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 11 2 (2000) 111-117
134. Daly M., and Obrams G.I. Epidemiology and risk assessment for ovarian cancer. Semin Oncol 25 3 (1998) 255-264
135. Hankinson S.E., Hunter D.J., Colditz G.A., et al. Tubal ligation, hysterectomy, and risk of ovarian cancer. JAMA 270 23 (1993) 2813-2818
136. Narod S.A., Sun P., Ghadirian P., et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet 357 9267 (2001) 1467-1470
137. Society of Gynecologic Oncologists Clinical Practice Committee. Statement on prophylactic salpingo-oophorectomy. Gynecol Oncol 98 (2005) 179-181
138. U.S. Preventative Services Task Force. Screening for ovarian cancer: recommendation statement. Ann Fam Med 2 3 (2004) 260-262
139. ACOG Committee on gynecologic practice, in association with the Society of Gynecologic Oncology. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Gynecol Oncol 87 3 (2002) 237-239
140. Aarnio M., Sankila R., Pukkala E., et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81 2 (1999) 214-218
141. National Comprehensive Cancer Network (NCCN) Guidelines for hereditary breast and/or ovarian cancer. Available at: www.nccn.com/physician_gls/index.html. Accessed October 30, 2007.
142. Scheuer L., Kauff N., Robson M., et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20 5 (2002) 1260-1268